Comparative Pharmacology
Head-to-head clinical analysis: EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE BROMPHENIRAMINE MALEATE versus EMERPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE BROMPHENIRAMINE MALEATE versus EMERPHED.
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE vs EMERPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Brompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, alleviating symptoms of allergic rhinitis.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
1 tablet orally every 12 hours. Each tablet contains pseudoephedrine HCl 120 mg and brompheniramine maleate 4 mg.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
None Documented
None Documented
Pseudoephedrine: 4-6 hours (range 3-16 hours); prolonged in alkaline urine or renal impairment. Brompheniramine: 11-27 hours (mean ~24 hours); prolonged in elderly or hepatic impairment.
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Pseudoephedrine: ~70-90% excreted unchanged in urine, with the remainder as inactive metabolites; renal elimination depends on urine pH (acidic urine increases excretion). Brompheniramine: ~75% metabolized in liver; renal excretion of metabolites and <5% unchanged; biliary/fecal elimination is minor.
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Category A/B
Category C
Sympathomimetic
Sympathomimetic